bioAffinity receives US patent allowance for AI-driven lung cancer diagnostic

bioAffinity Technologies, Inc.

USPTO allowed patent covering AI-built algorithm and flow cytometry platform for CyPath Lung test.
Patent titled 'Detection of Early-Stage Lung Cancer in Sputum using Automated Flow Cytometry and Machine Learning'.
CyPath Lung uses TCPP porphyrin and AI to detect lung cancer in sputum; clinical results: 92% sensitivity, 87% specificity, 88% accuracy.
Global patent estate now includes 18 awarded and 33 pending patents across 12 countries.
Diagnostic aims to detect early-stage lung cancer (Stage 1A) noninvasively, potentially curative.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.